SciELO - Scientific Electronic Library Online

 
vol.19 número1Relación del tamaño tumoral y extensión extratiroidea con la recaída local en el cáncer diferenciado de tiroides en población mexicana índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Gaceta mexicana de oncología

versão On-line ISSN 2565-005Xversão impressa ISSN 1665-9201

Resumo

RIVERA-CORTEZ, José de Jesús; PEREZ-PEREZ, Perla  e  CARDENAS-CARDENAS, Eduardo. Adverse effects of cabazitaxel at a dose of 20 mg/m2 vs. 25 mg/m2 in patients with resistant castration prostate cancer: retrospective analysis of case-series. Gac. mex. oncol. [online]. 2020, vol.19, n.1, pp.3-6.  Epub 30-Abr-2021. ISSN 2565-005X.  https://doi.org/10.24875/j.gamo.19000307.

Introduction:

In patients with resistant castration prostate cancer (RCPC), the TROPIC study established cabazitaxel 25 mg/ m2 as the standard second-line chemotherapy. In order to reduce the adverse effects, the PROSELICA study evaluated whether the decrease in the dose of cabazitaxel at 20 mg/m2 was not inferior fulfilling the objective. We propose this study to know the side effects of cabazitaxel in our population

Materials and Methods:

Patients > 18 years with RCPC, treated with cabazitaxel at a dose of 20 mg/m2 and 25 mg/m2, from 2014 to 2017, in a population of Centro Médico Nacional 20 de Noviembre, ISSSTE

Results:

41 patients were recruited. In both groups the most common toxicity was diarrhea in > 90% of the patients, however, grade 3-4 diarrhea in the 20 mg/m2 cabazitaxel group was 24% compared to the 25 mg/m2 group of 31.2%. A 12% of febrile neutropenia was observed in the control group compared to none patient at a dose of 20 mg/m2

Conclusions:

In our population, better tolerance of cabazitaxel at a dose of 20 mg/m2 compared to 25 mg/m2 is corroborated, we believe that the use of such dose should be a standard, as part of the tools available for the RCPC.

Palavras-chave : Cabazitaxel 20 mg/m2; Resistant castration prostate cancer; Second line; Adverse effects.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )